Cite
HARVARD Citation
Regidor, B. et al. (2023). Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody. European journal of haematology. pp. 222-223. [Online].